Drug Search Results
More Filters [+]

Atazanavir

Alternative Names: atazanavir, reyataz, bms-232632, evotaz
Latest Update: 2024-10-23
Latest Update Note: Clinical Trial Update

Product Description

Atazanavir is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children who are at least 3 months of age and weigh at least 22 lb (10 kg). Atazanavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although atazanavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a603019.html)

Mechanisms of Action: HIV Protease Inhibitor,Protease Inhibitor,UGT1A1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: HIV Infections

Known Adverse Events: Depressive Disorder | Abdominal Pain | Dizziness | Headache | Pain Unspecified | Myalgia | Diarrhea

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atazanavir

Countries in Clinic: Australia, Burkina Faso, Cameroon, Ivory Coast, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: HIV Infections

Phase 1: Healthy Volunteers|Malnutrition

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MODERATO

P3

Active, not recruiting

HIV Infections

2025-02-05

AI424-578

P1

Completed

Malnutrition

2022-07-05

28%

2006-7041-83/hah

P1

Not yet recruiting

Healthy Volunteers

None

Recent News Events